Xuelin Huang, Ph.D.

Peer-Reviewed Articles

1. Jayasekera J, Schechter CB, Sparano JA, Jagsi R, White J, Chapman JW, Whelan T, Anderson SJ, Fyles AW, Sauerbrei W, Zellars RC, Li Y, Song J, Huang X, Julian TB, Luta G, Berry DA, Feuer EJ, Mandelblatt J, CISNET-BOLD Collaborative Group. Effects of Radiotherapy in Early-Stage, Low-Recurrence Risk, Hormone-Sensitive Breast Cancer. J Natl Cancer Inst 110(12):1370-1379. e-Pub 2018. PMID: 30239794.
2. Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Jabbour E. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 59(4):1-8, 2018. e-Pub 2017. PMID: 28718728.
3. Ravandi F, Jorgensen J, Borthakur G, Jabbour E, Kadia T, Pierce S, Brandt M, Wang S, Konoplev S, Wang X, Huang X, Daver N, DiNardo C, Andreeff M, Konopleva M, Garcia-Manero G, Cortes J, Kantarjian H. Persistence of Minimal Residual Disease Assessed by Multi-Parameter Flow Cytometry is Highly Prognostic in Younger Patients with AML. Cancer 123(3):426-435, 2017.
4. Montalban-Bravo G, Huang X, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A Clinical Trial For Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes Not Eligible for Standard Clinical Trials. Leukemia(16-LEU-0930R). e-Pub 2016. PMID: 27795561.
5. Carter BZ, Mak PY, Mu H, Zhou H, Mak DH, Schober W, Leverson JD, Zhang B, Bhatia R, Huang X, Cortes J, Kantarjian H, Konopleva M, Andreeff M. Combined Targeting of BCL-2 and BCR-ABL Tyrosine Kinase Eradicates Chronic Myeloid Leukemia Stem Cells. Sci Transl Med 8(355):355ra117, 2016. PMID: 27605552.
6. Burger JA, Keating MJ, Wierda WG, Hartmann E, Hoellenriegel J, Rosin NY, de Weerdt I, Jeyakumar G, Ferrajoli A, Cardenas-Turanzas M, Lerner S, Jorgensen JL, Nogueras-González GM, Zacharian G, Huang X, Kantarjian H, Garg N, Rosenwald A, O'Brien S. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol 15(10):1090-9, 2014. e-Pub 2014. PMID: 25150798.
7. Quintás-Cardama A, Choi S, Kantarjian H, Jabbour E, Huang X, Cortes J. Predicting Outcomes in Patients with Chronic Myeloid Leukemia at any Time During Tyrosine Kinase Inhibitor Therapy. Clin Lymphoma Myeloma Leuk 14(4):327-334.e8, 2014. e-Pub 2014. PMID: 24594142.
8. Huang X, Ning J, Wahed AS. Optimization of Individualized Dynamic Treatment Regimes for Recurrent Diseases. Stat Med 33(14):2363-78, 2014. e-Pub 2014. PMID: 24510534.
9. Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤ 60 years with newly diagnosed acute myeloid leukemia (AML). Am J Hematol 88(11):961-6, 2013. e-Pub 2013. PMID: 23877926.
10. Rao X, Lai D, Huang X. A new method for quantitative real-time polymerase chain reaction data analysis. J Comput Biol 20(9):703-11, 2013. e-Pub 2013. PMID: 23841653.
11. Ravandi F, Jorgensen JL, Thomas DA, O'Brien S, Garris R, Faderl S, Huang X, Wen S, Burger JA, Ferrajoli A, Kebriaei P, Champlin RE, Estrov Z, Challagundla P, Wang SA, Luthra R, Cortes JE, Kantarjian HM. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood 122(7):1214-21, 2013. e-Pub 2013. PMID: 23836561.
12. Luo S, Yi M, Huang X, Hunt KK. A Bayesian Model for Misclassified Binary Outcomes and Correlated Survival Data with Applications to Breast Cancer. Stat Med 32(13):2320-2334, 2013. e-Pub 2012. PMID: 22996169.
13. Matin SF, Cormier JN, Ward JF, Pisters LL, Wood CG, Dinney CP, Royal RE, Huang X, Pettaway CA. Phase 1 prospective evaluation of the oncological adequacy of robotic assisted video-endoscopic inguinal lymphadenectomy in patients with penile carcinoma. BJU Int 111(4b):1068-74, 2013. e-Pub 2013. PMID: 23551693.
14. Choi S, Huang X, Chen YH. A class of semiparametric transformation models for survival data with a cured proportion. Lifetime Data Anal. e-Pub 2013. PMID: 23760878.
15. Choi S, Huang X. A general class of semiparametric transformation frailty models for nonproportional hazards survival data. Biometrics 68(4):1126-35, 2012. e-Pub 2012. PMID: 23005582.
16. Huang X, Ning J. Analysis of multi-stage treatments for recurrent diseases. Stat Med 31(24):2805-21, 2012. e-Pub 2012. PMID: 22826139.
17. Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer 118(18):4471-77, 2012. e-Pub 2012. PMID: 22282348.
18. Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 118(12):3123-7, 2012. e-Pub 2012. PMID: 22294282.
19. Kadia TM, Borthakur G, Garcia-Manero G, Faderl S, Jabbour E, Estrov Z, York S, Huang X, Pierce S, Brandt M, Koller C, Kantarjian HM, Ravandi F. Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol 157(3):312-20, 2012. e-Pub 2012. PMID: 22360602.
20. Kantarjian H, O'Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, Rios MB, Ravandi F, Faderl S, Kadia T, Borthakur G, Huang X, Champlin R, Talpaz M, Cortes J. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 119(9):1981-7, 2012. e-Pub 2012. PMID: 22228624.
21. Cai G, Li H, Lu Y, Huang X, Lee J, Müller P, Ji Y, Liang S. Accuracy of RNA-Seq and its dependence on sequencing depth. BMC Bioinformatics 13 Suppl 13:S5, 2012. e-Pub 2012. PMID: 23320920.
22. Kojima K, McQueen T, Chen Y, Jacamo R, Konopleva M, Shinojima N, Shpall E, Huang X, Andreeff M. p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12. Blood 118(16):4431-9, 2011. e-Pub 2011. PMID: 21868571.
23. Chen Y, Cortes J, Estrov Z, Faderl S, Qiao W, Abruzzo L, Garcia-Manero G, Pierce S, Huang X, Kebriaei P, Kadia T, De Lima M, Kantarjian H, Ravandi F. Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation. J Clin Oncol 29(18):2507-13, 2011. e-Pub 2011. PMID: 21555694.
24. Yuan Y, Huang X, Liu S. A Bayesian response-adaptive covariate-balanced randomization design with application to a leukemia clinical trial. Stat Med 30(11):1218-29, 2011. e-Pub 2011. PMID: 21432894.
25. Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S, LaPushin R, Xiao L, Huang X, Werner L, Neuberg D, Kantarjian H, O'Brien S, Wierda WG, Keating MJ, Rosenwald A, Burger JA. CCL3 (MIP-1a) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood 117(5):1662-9, 2011. e-Pub 2010. PMID: 21115978.
26. Ning J, Huang X. Response-Adaptive Randomization for Clinical Trials with Adjustment for Covariate Imbalance. Stat Med 29(17):1761-8, 2010. PMID: 20658546.
27. Walter RB, Kantarjian HM, Huang X, Pierce SA, Sun Z, Gundacker HM, Ravandi F, Faderl SH, Tallman MS, Appelbaum FR, Estey EH. Effect of Complete Remission and Responses Less Than Complete Remission on Survival in Acute Myeloid Leukemia: A Combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M.D. Anderson Cancer Center Study. J Clin Oncol 28(10):1766-71, 2010. e-Pub 2010. PMID: 20159819.
28. Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, Berry D, Ahmed S, Zhu W, Pierce S, Kondo Y, Oki Y, Jelinek J, Saba H, Estey E, Issa JP. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 28(4):605-13, 2010. e-Pub 2009. PMID: 20038729.
29. Borthakur G, Huang X, Kantarjian H, Faderl S, Ravandi F, Ferrajoli A, Torma R, Morris G, Berry D, Issa JP. Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. Leuk Lymphoma 51(1):73-8, 2010. PMID: 20017599.
30. Santos FP, Faderl S, Garcia-Manero G, Koller C, Beran M, O'Brien S, Pierce S, Freireich EJ, Huang X, Borthakur G, Bueso-Ramos C, de Lima M, Keating M, Cortes J, Kantarjian H, Ravandi F. Adult Acute Erythroleukemia: An analysis of 91 patients treated at a single institution. Leukemia 23(12):2275-80, 2009. e-Pub 2009. PMID: 19741728.
31. Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol 27(32):5425-30, 2009. e-Pub 2009. PMID: 19805674.
32. Konoplev S, Huang X, Drabkin HA, Koeppen H, Jones D, Kantarjian HM, Garcia-Manero G, Chen W, Medeiros LJ, Bueso-Ramos CE. Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis. Cancer 115(20):4737-44, 2009. PMID: 19637342.
33. Garg R, Faderl S, Garcia-Manero G, Cortes J, Koller C, Huang X, York S, Pierce S, Brandt M, Beran M, Borthakur G, Kantarjian H, Ravandi F. Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome. Leukemia 23(7):1297-302, 2009. e-Pub 2009. PMID: 19242494.
34. Huang X, Ning J, Li Y, Estey E, Issa JP, Berry DA. Using short-term response information to facilitate adaptive randomization for survival clinical trials. Stat Med 28(12):1680-9, 2009. PMID: 19326367.
35. Liu L, Huang X. Joint analysis of correlated repeated measures and recurrent events processes in the presence of death, with application to an AIDS study. Journal of the Royal statistical Society, Series C (Applied statistics) 58(1):65-81, 2009.
36. Huang X, Zhang N. Regression Survival Analysis with an Assumed Copula for Dependent Censoring: A Sensitivity Analysis Approach. Biometrics 64(4):1090-9, 2008. e-Pub 2008. PMID: 18266895.
37. Faderl S, Ferrajoli A, Wierda W, Huang X, Verstovsek S, Ravandi F, Estrov Z, Borthakur G, Kwari M, Kantarjian HM. Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer 113(8):2090-6, 2008. PMID: 18756533.
38. Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Borthakur G, Verstovsek S, Thomas DA, Kwari M, Kantarjian HM. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 112(5):1638-45, 2008. e-Pub 2008. PMID: 18565853.
39. Liu L, Huang X. The use of Gaussian quadrature for estimation in frailty proportional hazards models. Stat Med 27(14):2665-83, 2008. PMID: 17910008.
40. Anaya DA, Xing Y, Feng L, Huang X, Camacho LH, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Cormier JN. Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease. Cancer 112(9):2030-7, 2008. PMID: 18320602.
41. Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G, Wierda WG, Pierce S, Estey E, Liu J, Huang X, Kantarjian H. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 22(3):538-43, 2008. e-Pub 2007. PMID: 18079733.
42. O'Brien S, Ravandi F, Riehl T, Wierda W, Huang X, Tarrand J, O'Neal B, Kantarjian H, Keating M. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood 111(4):1816-9, 2008. e-Pub 2007. PMID: 18039954.
43. Kantarjian H, O'Brien S, Shan J, Huang X, Garcia-Manero G, Faderl S, Ravandi-Kashani F, Verstovsek S, Beth Rios M, Cortes J. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?. Cancer 112(4):837-45, 2008. PMID: 18085610.
44. Liu L, Huang X, O'Quigley J. Analysis of longitudinal data in the presence of informative observational times and a dependent terminal event, with application to medical cost data. Biometrics 64(3):950-8. e-Pub 2007. PMID: 18162110.
45. Huang X, Biswas S, Oki Y, Issa JP, Berry DA. A Parallel Phase I/II Clinical Trial Design for Combination Therapies. Biometrics 63(2):429-36, 2007. PMID: 17688495.
46. Huang X, Liu L. A Joint Frailty Model for Survival and Gap Times Between Recurrent Events. Biometrics 63(2):389-97, 2007. PMID: 17688491.
47. Konoplev S, Rassidakis GZ, Estey E, Kantarjian H, Liakou CI, Huang X, Xiao L, Andreeff M, Konopleva M, Medeiros LJ. Overexpression of CXCR4 Predicts Adverse Overall and Event-Free Survival in Patients with Unmutated FLT3 Acute Myeloid Leukemia with Normal Karyotype. Cancer 109(6):1152-6, 2007. PMID: 17315232.
48. Kantarjian HM, O'Brien S, Huang X, Garcia-Manero G, Ravandi F, Cortes J, Shan J, Davisson J, Bueso-Ramos CE, Issa JP. Survival Advantage with Decitabine Versus Intensive Chemotherapy in Patients with Higher Risk Myelodysplastic Syndrome: Comparison with Historical Experience. Cancer 109(6):1133-7, 2007. PMID: 17315156.
49. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109(1):52-7, 2007. e-Pub 2006. PMID: 16882708.
50. Huang X, Cormier JN, Pisters PW. Estimation of the Causal Effects on Survival of Two-Stage Nonrandomized Treatment Sequences for Recurrent Diseases. Biometrics 62(3):901-9, 2006. PMID: 16984334.
51. Ravandi F, Jorgensen JL, O'Brien SM, Verstovsek S, Koller CA, Faderl S, Giles FJ, Ferrajoli A, Wierda WG, Odinga S, Huang X, Thomas DA, Freireich EJ, Jones D, Keating MJ, Kantarjian HM. Eradication of minimal residual disease in hairy cell leukemia. Blood 107(12):4658-62, 2006. e-Pub 2006. PMID: 16497968.
52. Cormier JN, Xing Y, Feng L, Huang X, Davidson L, Gershenwald JE, Lee JE, Mansfield PF, Ross MI. Metastatic Melanoma to Lymph Nodes in Patients with Unknown Primary Sites. Cancer 106(9):2012-20, 2006. PMID: 16568458.
53. Huang X, Strawderman RL. A Note on Breslow Estimator for Survival Functions. Journal of Nonparametric Statistics 18(1):45-6, 2006. PMID: Not in PubMed.
54. Huang X, Biswas S, Estey EH, Berry DA. Building and validating a prognostic index for biomarker studies. Cancer Biomark 2(3-4):97-101, 2006. PMID: 17192064.
55. Shen Y, Huang X. Nonparametric Estimation of Asymptomatic Duration from a Randomized Prospective Cancer Screening Trial. Biometrics 61(4):992-9, 2005. PMID: 16401272.
56. Phongkitkarun S, Kobayashi S, Varavithya V, Huang X, Curley SA, Charnsangavej C. Bile Duct Complications of Hepatic Arterial Infusion Chemotherapy Evaluated by Helical CT. Clin Radiol 60(6):700-9, 2005. PMID: 16038698.
57. Cormier JN, Huang X, Xing Y, Thall PF, Wang X, Benjamin RS, Pollock RE, Antonescu CR, Maki RG, Brennan MF, Pisters PW. Cohort Analysis of Patients with Localized, High-Risk Extremity Soft Tissue Sarcoma Treated at Two Cancer Centers: Chemotherapy-Associated Outcomes. J Clin Oncol 22(22):4567-74, 2004. PMID: 15542808.
58. Liu L, Wolfe RA, Huang X. Shared Frailty Model for Recurrent Events and a Terminal Event. Biometrics 60(3):747-56, 2004. PMID: 15339298.
59. Huang X, Wolfe RA, Hu C. A Test for Informative Censoring in Clustered Survival Data. Stat Med 23(13):2089-107, 2004. PMID: 15211605.
60. Rosen DG, Huang X, Deavers MT, Malpica A, Silva EG, Liu J. Validation of Tissue Microarray Technology in Ovarian Carcinoma. Mod Pathol 17(7):790-7, 2004. PMID: 15073602.
61. Chang KC, Huang X, Medeiros LJ, Jones D. Germinal Center-Like Versus Undifferentiated Stromal Immunophenotypes in Follicular Lymphoma. J Pathol 201(3):404-12, 2003. PMID: 14595752.
62. Harrison RV, Janz NK, Wolfe RA, Tedeschi PJ, Stross JK, Huang X, McMahon LF, Jr. Characteristics of Primary Care Physicians and Their Practices Associated with Mammography Rates for Older Women. Cancer 98(9):1811-21, 2003. PMID: 14584062.
63. Harrison RV, Janz NK, Wolfe RA, Tedeschi PJ, Chernew M, Stross JK, Huang X, McMahon LF, Jr. Personalized Letter Increases Mammography Among Long-Term Noncompliant Medicare Beneficiaries: A Randomized Trial. Medical Care 41(3):375-85, 2003. PMID: 12618641.
64. Harrison RV, Janz NK, Wolfe RA, Tedeschi PJ, Huang X, McMahon LF, Jr. Five-Year Mammography Rates and Associated Factors for Older Women. Cancer 97(5):1147-55, 2003. PMID: 12599219.
65. Huang X, Wolfe RA. A Frailty Model for Informative Censoring. Biometrics 58(3):510-20, 2002. PMID: 12229985.